Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Granules India is currently trading at Rs. 366.00, up by 4.50 points or 1.24% from its previous closing of Rs. 361.50 on the BSE.
The scrip opened at Rs. 364.60 and has touched a high and low of Rs. 371.75 and Rs. 360.15 respectively. So far 43332 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 438.00 on 01-Dec-2020 and a 52 week low of Rs. 114.50 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 373.45 and Rs. 358.50 respectively. The current market cap of the company is Rs. 9177.59 crore.
The promoters holding in the company stood at 42.04%, while Institutions and Non-Institutions held 26.70% and 31.27% respectively.
Granules India has declared that the US Food & Drug Administration (US FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg, generic equivalent of Glumetza ER Tablets, 500 mg and 1000 mg, of Bausch Health US LLC (Bausch).
Metformin Hydrochloride ER Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Metformin Hydrochloride ER Tablets had U.S. sales of approximately $192 million for the most recent twelve months ending in November 2020 according to IQVIA Health.
Granules now has a total of 35 ANDA approvals from US FDA (34 Final approvals and 1 tentative approval). Glumetza is a trademark of Salix Pharmaceuticals, Inc. or its affiliates.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1515.00 |
| Dr. Reddys Lab | 6080.25 |
| Cipla | 1565.50 |
| Zydus Lifesciences | 1110.95 |
| Lupin | 1601.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
